The CSL Limited (ASX:CSL) share price is falling

The CSL Limited (ASX: CSL) share price is down 0.9% to $185.78 at the time of writing after a succession of declines since September – but the S&P/ASX 200 declines are not where CSL finds itself most at home.

The one-year return on CSL shares is still 29.78%, but investors acclimatised to its consistent inclines could be excused for being slightly nervous about the CSL share price over the last two months.

For most healthcare-focused investors, CSL is the ultimate holding, with the biopharmaceutical giant considered one of the highest-quality businesses on the ASX and long-term growth in its plasma and influenza business units almost guaranteed.

The recent slow down in price is likely a response to bearishness in the overall market of late, and CSL still manages to outpace sector peer Cochlear Limited (ASX: COH) in terms of value and growth, with the Cochlear share price down today at $172.07.

ResMed Inc (ASX: RMD) is another option to consider in healthcare and its also in a share price slump right now.

Japanese Billionaire’s Prediction Will Give You Goosebumps

When a veritable investing and entrepreneurial genius speaks, it pays to listen.

In fact, he's now preparing a $100B "war chest" to invest entirely in this "terrifying" new technology, which could spell huge profits for investors.

Click here to learn about this technology and how you can profit!

Motley Fool contributor Carin Pickworth has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.